Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
- Conditions
- Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT05678205
- Locations
- 🇺🇸
Oregon Health Science University (OHSU), Portland, Oregon, United States
🇰🇷The Catholic University of Korea, St. Vincent's Hospital, Suwon, Gyeonggi-do, Korea, Republic of
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Drug: Single Injection of IVS-3001- Anti - HLA-G CAR-T cellsDrug: Fludarabine phosphateDrug: CyclophosphamideProcedure: leukapheresis
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 117
- Registration Number
- NCT05672459
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
- Conditions
- Richter SyndromeRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic Leukemia
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyDrug: CyclophosphamideDrug: FludarabineDrug: IbrutinibBiological: Lisocabtagene MaraleucelBiological: NivolumabProcedure: PheresisProcedure: Positron Emission Tomography
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05672173
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
- Conditions
- AML, Adult
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 19
- Registration Number
- NCT05665075
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Natural Killer(NK) Cell Therapy in r/r AML
- Conditions
- AML, Adult
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 18
- Registration Number
- NCT05665114
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
- Conditions
- CLL/SLLNHLMantle Cell LymphomaFollicular LymphomaLarge B-cell LymphomaIndolent B-Cell Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Synthekine
- Target Recruit Count
- 36
- Registration Number
- NCT05665062
- Locations
- 🇺🇸
Roswell Park, Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸City of Hope, Duarte, California, United States
EBV CAR-T Cells for Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2022-12-19
- Target Recruit Count
- 24
- Registration Number
- NCT05654077
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
- Conditions
- DLBCLMarginal Zone LymphomaFollicular LymphomaB-cell LymphomaPrimary Mediastinal Large B Cell LymphomaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05653271
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
- Conditions
- Solid Tumor
- Interventions
- Biological: Tumor Infiltrating LymphocytesDrug: FludarabineDrug: Cyclophosphamide CapsulesDrug: IL-2
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05649618
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Biological: TCR-T cellsDrug: FludarabineDrug: Cyclophosphamide CapsulesDrug: Albumin-bound paclitaxelDrug: IL-2
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05648994
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.